Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis (ULTRA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03711448 |
|
Recruitment Status :
Recruiting
First Posted : October 18, 2018
Last Update Posted : October 14, 2022
|
Sponsor:
Centre Hospitalier Universitaire Dijon
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 2025 |
| Estimated Study Completion Date : | January 2025 |